Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540879 | 0.93 | MAOB (0.44) | MAOBMAOATAAR1APPFFAR1 | |
| SCHEMBL6976874 | 0.92 | MAOB (0.46) | MAOBMAOAAPPNPC1RAB9A | |
| SCHEMBL15079869 | 0.86 | MAOB (0.58) | MAOBMAOATAAR1APPNPC1 | |
| SCHEMBL695776 | 0.83 | MAOA (0.48) | MAOBMAOATAAR1APPNPC1 | |
| SCHEMBL10840203 | 0.83 | KCNH2 (0.51) | MAOBMAOATAAR1NPC1RAB9A | |
| SCHEMBL832412 | 0.83 | GPR84 (0.50) | MAOBMAOATAAR1APPNPC1 | |
| SCHEMBL697362 | 0.82 | MAOB (0.61) | MAOBMAOAAPPNPC1RAB9A | |
| SCHEMBL832700 | 0.82 | NPC1 (0.61) | MAOBMAOANPC1RAB9AFFAR1 | |
| SCHEMBL5535321 | 0.82 | MAOB (0.49) | MAOBTAAR1 | |
| SCHEMBL833408 | 0.81 | KCNH2 (0.49) | MAOBTAAR1APPFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | claimed |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | claimed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| CN-108409837-B | Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2021-09-24 | — | — | CN | disclosed |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | disclosed |
| WO-2019170046-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2019-09-12 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOB 2140/4885MAOA 2885/4885TAAR1 364/4885 |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | VIP, CUTA, MGAM | MAOB 2702/4885MAOA 2941/4885TAAR1 3759/4885 |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | VIP, CUTA, MGAM | MAOB 2702/4885MAOA 2941/4885TAAR1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.